It is known that the phase 1 clinical trial of the mouthwash and swallowable oral vaccine QYNDR (pronounced kinder) has been completed and is currently on hold. Clinical trial results conducted in New Zealand offer hope that the vaccine produced by US Specialty Formulations may be effective in protecting against a number of circulating Covid-19 variants, but has yet to be peer-reviewed.Phase 1 clinical trial completed, awaiting funding from investors
According to Kyle Flanigan, founder of vaccine manufacturer US Specialty Formulations, developing a vaccine that works through the digestive system is a very difficult process. It also needs funding from investors to advance the additional clinical research needed to study and market this vaccine.
The same big names are mentioned when it comes to Covid 19 vaccines; Pfizer, Moderna, Johnson & Johnson, AstraZeneca. But researchers around the world are trying to find new forms of vaccines, such as nasal vaccines, which were recently launched in China and India. Researchers are still waiting for data to confirm whether mucosal vaccines stop infections.
Mucosal vaccines are different from traditional vaccine types because; They enter through our mucous membranes, either through the mucosa surrounding our nose (such as the nasal Covid-19 vaccine) or through our intestines (such as QYNDR). It is supported as a viable and even convenient option in the fight against Covid-19 infections, due to the different types of immunity they produce and the effect where the virus enters our body. On the other hand, although it causes much less damage compared to January 2021, Covid 19 is still not completely over.
20942
